Intracochlear administration of DB-OTO Gene Therapy in pediatric patients with profound hearing loss due to otoferlin mutations: the CHORD Phase 1 / 2 open-label trial

Zoom

Eduardo Corrales, MD

Section Chief, Otology, Neurotology and Skull Base Surgery
Brigham and Women’s Hospital

Assistant Professor
Department of Otolaryngology—Head and Neck Surgery 
Harvard Medical School

 

1. Learn from state of the art gene therapy for pediatric patients with deafness. 

2. Identify the auditory neuropathy spectrum disease of pediatric patients with otoferlin deficiency.

3. Be able to acknowledge gene therapy treatment for patients with otoferlin mutation and profound sensorineural hearing loss,